The global osteoporosis drugs market is expected to grow from USD 1.48 billion in 2018 to USD 1.97 billion by 2026, at a CAGR of 5.73% during the forecast period 2019-2026.
The weakening of bones is known as osteoporosis due to lower bone mass that results in micro-architectural deterioration of bone tissue and leads to higher risk of a broken fracture. The osteoporosis makes bones weaker and breakable. It generally occurs at an advanced age of an individual and is mostly seen in women than males. Osteoporosis happens due to lower-than-normal maximum bone mass and greater-than-normal bone loss. There is an increase in bone loss after menopause due to lower levels of estrogen. Osteoporosis could also occur due to a number of diseases or treatments, it also include anorexia, alcoholism, kidney disease, hyperthyroidism, and surgical removal of the ovaries. Certain medications may increase the rate of bone loss, including some antiseizure medications, proton pump inhibitors, chemotherapy, selective serotonin reuptake inhibitors, and glucocorticosteroids. Smoking and less or no exercise are also the risk factors. The increasing awareness for osteoporosis care is the major trend that is witnessed in the osteoporosis drugs market. According to National Institutes of Health Osteoporosis and Related Bone Diseases, the changing lifestyle that includes alcohol, sedentary lifestyle, and smoking will highly promote osteoporosis in men. The increasing prevalence of osteoporosis and investments in the discovery and development of drugs to treat osteoporosis is driving the osteoporosis drugs market.
Increasing geriatric population, increasing prevalence of osteoporosis in postmenopausal women, changing lifestyles impinging bone health are the key driving factors for the osteoporosis drugs market. In addition, growing awareness about osteoporotic care, and increasing investment in drug discovery and development will lead the growth of the osteoporosis drugs market in a couple of years. The side effects of osteoporosis drugs and patent expiration of osteoporosis drug may limit the growth of the market. However, increasing R&D investment in drug discovery and development and increasing healthcare expenditure is expected to boost the osteoporosis drugs market over the forecast period.
Key players operating in the global osteoporosis drugs market are Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche, Teva Pharmaceutical Industries, Ltd., GlaxoSmithKline plc, Novartis International AG, Merck & Co. Inc., Amgen Inc, Radius Health, Inc., Novo Nordisk A/S, Actavis plc, GlaxoSmithKline plc, and among others.
Osteoporosis Drugs Market By Drug Type
Osteoporosis Drugs Market By Application
Osteoporosis DrugsMarket By Geography
Bisphosphonates segment held the highest market size of around USD 445.74 million in 2017
Drug class segment includes bisphosphonates, selective estrogen inhibitors modulator (SERM), parathyroid hormone therapy, calcitonin, rank ligand inhibitors, generics, and others. The bisphosphonates segment held the highest market size of around USD 445.74 million in 2017. Bisphosphonates are the most commonly prescribed medication for treatment and prevention of osteoporosis.
Oral segment registered the highest market share of 56.18% in 2017
Route of administration segment covers oral, injectable, and others. The oral segment registered the highest market share of 56.18% in 2017 owing to high preference of oral osteoporosis drugs, ease of availability, and is commonly prescribed medication for treatment.
Female segment is anticipated to hold the largest share of 55.16% during the forecast period
Gender segment consists of male and female. The female segment is anticipated to hold the largest share of 55.16% during the forecast period owing to increasing the risk of fractures, mainly in wrist, hip, and spinal vertebrae are seen more in women’s over the age of 50. According to International Osteoporosis Foundation (IOF), the number of women suffering from osteoporosis has crossed more than 200 million globally.
Regional Segment Analysis of the Osteoporosis drugs Market
North America (U.S. , Canada, Mexico)
Europe (Germany, France, U.K., Italy, Spain, Rest of the Europe)
Asia-Pacific (China, Japan India, Rest of APAC)
South America (Brazil and Rest of South America)
Middle East and Africa (UAE, South Africa, Rest of MEA)
The market is analysed on the basis of five regions namely North America, Europe, Asia Pacific, South America, and Middle East and Africa. North America region dominated the global osteoporosis drugs market with USD 566.35 million in 2017 where as the Asia Pacific region held the second dominant position in the market. The presence of well-established medical & healthcare infrastructure, substantial investments in the healthcare activities, favourable R& D policies of the government towards the osteoporosis drug applications are the major trends for the increasing osteoporosis drugs market in North America region. Asia Pacific region holds second dominant position in the due to the global osteoporosis drugs market due to increasing occurrences of osteoporosis in Asia-Pacific, rising disposable income, persistent infrastructural improvements in healthcare facilities, and consistent R&D investments deployed by the prominent players in this region.